Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 0.58 |
| ▸ | MASP2 | O00187 | 1/20 | 0.58 |
| ▸ | CMA1 | P23946 | 8/20 | 0.57 |
| ▸ | ACP3 | P15309 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438416 | 0.86 | CTSG (0.51) | CTSGMASP2CMA1ACP3 | |
| SCHEMBL1078569 | 0.80 | CTSG (0.75) | CTSGMASP2CMA1ACP3 | |
| SCHEMBL4140309 | 0.80 | CMA1 (0.67) | CTSGMASP2CMA1ACP3 | |
| SCHEMBL405682 | 0.79 | CMA1 (0.63) | CTSGMASP2CMA1ACP3HPGD | |
| SCHEMBL4181576 | 0.78 | CTSG (0.73) | CTSGMASP2CMA1ACP3 | |
| SCHEMBL4144945 | 0.77 | CMA1 (0.60) | CTSGMASP2CMA1ACP3 | |
| SCHEMBL12523113 | 0.77 | CTSG (0.72) | CTSGMASP2CMA1ACP3 | |
| SCHEMBL1614762 | 0.77 | CTSG (0.82) | CTSGMASP2CMA1ACP3SIGMAR1 | |
| SCHEMBL4191174 | 0.76 | CTSG (0.72) | CTSGMASP2CMA1ACP3 | |
| SCHEMBL4189780 | 0.76 | CTSG (0.70) | CTSGMASP2CMA1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| JP-2011500682-A | — | — | 2011-01-06 | — | — | JP | claimed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | claimed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CTSG 166/4885MASP2 553/4885CMA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.